InsiderTrades

Form 4 for ISRG Intuitive Surgical

Accepted 2023-04-24 00:00:00 ET · period of report 2023-04-21 · accession 0001035267-23-000097 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-04-24 2023-04-21 ISRG BARRATT CRAIG H Dir S - Sale+OE $297.92 -6,000 0 -100% -$1.79M
DM 2023-04-24 2023-04-21 ISRG BARRATT CRAIG H Dir M - OptEx $41.26 +6,000 2,000 New +$247.6K
DM 2023-04-24 2023-04-21 ISRG BARRATT CRAIG H Dir M - OptEx $0.00 -6,000 5,567 -52% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-04-21 S D 2,000 $297.92 0 D — — (F2) The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.42 to $299.21 as follows: 384 shares at $296.42 - $297.12; 1,216 shares at $297.57 -$298.50; 400 shares at $298.58 - $299.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
2 Common Common Stock 2023-04-21 S D 2,000 $297.92 0 D — — (F4) The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.42 to $299.23 as follows: 366 shares sold at $296.42 - 297.14; 1,254 shares sold at $297.52 - $298.46; 380 shares sold at $298.63 - $299.23. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3 Common Common Stock 2023-04-21 M A 2,000 $41.26 2,000 D — —
4 Common Common Stock 2023-04-21 S D 2,000 $297.93 0 D — — (F3) The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.56 to $299.20 as follows: 404 shares sold at $296.56 - 297.56; 1,201 shares sold at $297.6 - $298.59; and 395 shares sold at $298.61 - $299.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5 Common Common Stock 2023-04-21 M A 2,000 $41.26 2,000 D — —
6 Common Common Stock 2023-04-21 M A 2,000 $41.26 2,000 D — —
7 Derivative Non-Qualified Stock Option (right to buy) 2023-04-21 M D 2,000 $0.00 7,567 D $41.26 · — to 2024-04-24 2,000 Common Stock (F5) Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.
8 Derivative Non-Qualified Stock Option (right to buy) 2023-04-21 M D 2,000 $0.00 3,567 D $41.26 · — to 2024-04-24 2,000 Common Stock (F5) Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.
9 Derivative Non-Qualified Stock Option (right to buy) 2023-04-21 M D 2,000 $0.00 5,567 D $41.26 · — to 2024-04-24 2,000 Common Stock (F5) Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.